Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > REGULATORY
REGULATORY
- Broad Perspective Important for Vaccination Policy: CDC Official
June 23, 2014
- LDP OKs Revised Version of Draft Economic, Fiscal Policy Guidelines
June 20, 2014
- First Generics of Diovan, Blopress AGs Join Reimbursement List
June 20, 2014
- PAFSC’s Second Committee to Discuss Approval for IFN-Free Hepatitis C Treatments on June 26
June 19, 2014
- Drug Price Settlement Rate for March 2014 at 98.4%: MHLW
June 19, 2014
- LDP Members Request Govt to Stay with Current Biennial NHI Price Revision
June 18, 2014
- MHLW on Tap to Launch Expedited Drug Review System in 2015
June 18, 2014
- Govt Weighs Applying Mixed Care Scheme to Low Cost-Effective Drugs: Draft Growth Strategy
June 17, 2014
- PMDA Reviewing Osteoporosis Treatment Forteo for Risk of Shock, Anaphylaxis
June 17, 2014
- “Annual” NHI Price Revision Erased from Gov’t Draft Policy Blueprint
June 16, 2014
- Regulatory Reform Proposal Including Expansion of Mixed Care Use Submitted to Prime Minister
June 16, 2014
- LDP Members with Vested Interests Slam Annual NHI Price Revision
June 12, 2014
- MHLW Panel OKs Draft Report on Medical Database Project, but Further Discussion Needed for Drug Makers’ Usage
June 12, 2014
- Expansion of “Mixed Care” Cited in Outline for New Growth Strategy
June 12, 2014
- MHLW to Seek Opinions on Abe’s New Mixed Care Plan from Advisory Panels
June 11, 2014
- PM Abe Vows to Forge New System to Accelerate Mixed Care
June 11, 2014
- Health Minister Still Cautious about Annual Drug Price Revision
June 11, 2014
- Ex-Novartis Employee Nabbed over Diovan Data Tampering: Reports
June 11, 2014
- Govt Tilting Toward Etching Annual NHI Price Revision in Fiscal Blueprint
June 10, 2014
- No Complaints Received So Far for Penalty Fee Cuts: MHLW Official
June 10, 2014
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…